Healthcare Media Reacting To Trump Win
A series of articles appeared today reacting to Donald Trump’s victory in the presidential election.
The articles predict as expected that the Exchanges and Medicaid will be reined in through a number of regulatory and statutory efforts. It notes that Trump may not again go after the Affordable Care Act (ACA), but that extension of the enhanced premium subsidies in the Exchanges are very much in doubt. At the same time, his incoming VP JD Vance outlined a potential change to premium setting in Exchanges.
On Medicare Advantage (MA), Trump is said to be much more enamored with the program as an alternative to the traditional system. I, however, feel Trump and lawmakers will still seek some reforms and savings in MA.
Pharmacy benefits manager (PBM) reform likely moves forward, given bipartisan congressional support and previous positions taken by the former president.
Trump is also seen as less antitrust focused than the current administration. But again, many GOP lawmakers in the Senate have grave concerns about consolidation.
An open question is what will happen to Medicare drug price negotiations. Trump took no real position on it during the campaign and he had policies that were in favor of drug price reform and reductions.
Health insurer stocks, especially those focused on MA, were up after Tuesday considerably.
Additional articles: https://www.fiercehealthcare.com/payers/insurers-prep-trump-admin-friendly-medicare-advantage-and-mergers-hostile-medicaid-and-aca and https://www.modernhealthcare.com/politics-policy/trump-healthcare-policy-medicare-aca-second-term and https://www.modernhealthcare.com/insurance/unitedhealth-humana-cvs-stocks-trump-election-win and https://insidehealthpolicy.com/daily-news/fate-ira-negotiations-uncertain-after-trump-election-victory
#election2024 #healthcare #healthcarereform #trump
(Some articles may require a subscription.)